Jupiter Neurosciences, Inc. announced the publication in the Journal of Alzheimer's Disease of "JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model." This research, performed in collaboration with the University of Miami Miller School of Medicine demonstrated that a novel, oral formulation of resveratrol, JOTROL, was able to deliver therapeutically viable levels of resveratrol in a disease mouse model of Alzheimer's disease (AD). The results showed that JOTROL significantly increased bioavailability over non-formulated resveratrol and that treatment resulted in AD-related gene expression changes, as well as changes in inflammatory gene and cytokine levels. JOTROL may be effective as a prophylaxis and/or treatment for AD through increased expression and/or activation of neuroprotective genes, suppression of pro-inflammatory genes, and regulation of central and peripheral cytokine levels.
Jupiter Neurosciences, Inc.
Equities
JUNS
US48208B2034
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+23.13% | 46.93B | |
+37.52% | 39.08B | |
-8.73% | 38.48B | |
+28.09% | 31.01B | |
-12.26% | 26.14B | |
+10.57% | 25.88B | |
+45.05% | 14.15B | |
+32.23% | 12.53B | |
-6.56% | 11.36B |